2. Academic Validation
  3. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

  • Leuk Lymphoma. 2022 Mar;63(3):738-742. doi: 10.1080/10428194.2021.2005045.
Ricardo D Parrondo 1,  Aneel Paulus 1,  Victoria Alegria 1,  David Liebowitz 2,  Chelsea Johnson 2,  Raphael Clynes 2,  Vivek Roy 1,  David M Menke 3,  Liuyan Jiang 3,  Asher A Chanan-Khan 1,  Sikander Ailawadhi 1
Affiliations

Affiliations

  • 1 Deparment of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
  • 2 Xencor, Inc, Monrovia, CA, USA.
  • 3 Department of Pathology, Mayo Clinic Florida, Jacksonville, FL, USA.
PMID: 34781809 DOI: 10.1080/10428194.2021.2005045
Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99776
    99.12%, Anti-CD3/CD20 Antibody